市場調查報告書
商品編碼
1087243

代謝障礙治療藥的全球市場:產業分析,趨勢,市場規模,預測(∼2028年)

Metabolic Disorders Therapeutics Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2028

出版日期: | 出版商: Infinium Global Research (IGR) | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球代謝障礙治療藥的市場規模在2022∼2028年的預測期間中預計將以7%的年複合成長率成長。

本報告提供全球代謝障礙治療藥市場相關調查分析,提供市場促進因素,阻礙因素,市場機會,宏觀指標分析,疾病類型·產品·各地區市場分析,企業簡介相關資訊。

目錄

第1章 序文

  • 報告的說明
  • 調查方法
  • 研究途徑

第2章 摘要整理

  • 代謝障礙治療藥市場概況
  • 代謝障礙治療藥市場預測
  • 代謝障礙治療藥市場地區的亮點

第3章 全球代謝障礙治療藥:市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 代謝障礙治療藥市場的COVID-19影響分析
  • 波特的五力分析
  • IGR-成長矩陣分析
    • IGR-成長矩陣分析:各疾病類型
    • IGR-成長矩陣分析:各產品
    • IGR-成長矩陣分析:各地區
  • 代謝障礙治療藥市場價值鏈分析

第4章 代謝障礙治療藥市場宏觀指標分析

第5章 全球代謝障礙治療藥市場:各疾病類型

  • 糖尿病
  • 肥胖症
  • 高膽固醇症
  • 溶酶體貯積病

第6章 全球代謝障礙治療藥市場:各產品

  • 異染性腦白質營養不良
  • 球形腦白質營養不良
  • 肝性腦病
  • 其他

第7章 全球代謝障礙治療藥市場:各地區(2022∼2028年)

  • 北美
    • 各疾病類型
    • 各產品
    • 各國
  • 歐洲
    • 各疾病類型
    • 各產品
    • 各國
  • 亞太地區
    • 各疾病類型
    • 各產品
    • 各國
  • 其他地區
    • 各疾病類型
    • 各產品
    • 各子地區

第8章 企業簡介和競爭情形

  • 競爭情形
  • 企業簡介
    • Astazeneca Plc
    • Novo Nordisk
    • Sanofi
    • Merck
    • Eli Lily
    • Abbvie
    • Actelion Pharmaceuticals
    • Amicus Therapeutics
    • Arena Pharmaceuticals
    • Biocon
目錄
Product Code: HC0054

The report on the global metabolic disorders therapeutics market provides qualitative and quantitative analysis for the period from 2020 to 2028. The report predicts the global metabolic disorders therapeutics market to grow with a CAGR of 7% over the forecast period from 2022-2028. The study on metabolic disorders therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2020 to 2028.

The report on metabolic disorders therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global metabolic disorders therapeutics market over the period of 2020 to 2028. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global metabolic disorders therapeutics market over the period of 2020 to 2028. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • Growing collaborations of academia-industry for drug development
  • Growing diabetic population

2) Restraints

  • Availability of alternative treatments

3) Opportunities

  • Strategic collaborations and acquisition and increased R & D investment

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

  • 1. Key Opinion Leaders associated with Infinium Global Research
  • 2. Internal and External subject matter experts
  • 3. Professionals and participants from the industry

Our primary research respondents typically include

  • 1. Executives working with leading companies in the market under review
  • 2. Product/brand/marketing managers
  • 3. CXO level executives
  • 4. Regional/zonal/ country managers
  • 5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

  • 1. Company reports and publications
  • 2. Government/institutional publications
  • 3. Trade and associations journals
  • 4. Databases such as WTO, OECD, World Bank, and among others.
  • 5. Websites and publications by research agencies

Segment Covered

The global metabolic disorders therapeutics market is segmented on the basis of disease type, and product.

The Global Metabolic Disorders Therapeutics Market by Disease Type

  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Lysosomal Storage Disease

The Global Metabolic Disorders Therapeutics Market by Product

  • Metachromatic Leukodystrophy
  • Globoid Leukodystrophy
  • Hepatic Encephalopathy
  • Others

Company Profiles

The companies covered in the report include

  • Astazeneca Plc
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lily
  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Biocon

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the metabolic disorders therapeutics market.

2. Complete coverage of all the segments in the metabolic disorders therapeutics market to analyze the trends, developments in the global market and forecast of market size up to 2028.

3. Comprehensive analysis of the companies operating in the global metabolic disorders therapeutics market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methods
  • 1.3. Research Approaches

2. Executive Summary

  • 2.1. Metabolic Disorders Therapeutics Market Highlights
  • 2.2. Metabolic Disorders Therapeutics Market Projection
  • 2.3. Metabolic Disorders Therapeutics Market Regional Highlights

3. Global Metabolic Disorders Therapeutics Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Analysis of COVID-19 impact on the Metabolic Disorders Therapeutics Market
  • 3.4. Porter's Five Forces Analysis
  • 3.5. IGR-Growth Matrix Analysis
    • 3.5.1. IGR-Growth Matrix Analysis by Disease Type
    • 3.5.2. IGR-Growth Matrix Analysis by Product
    • 3.5.3. IGR-Growth Matrix Analysis by Region
  • 3.6. Value Chain Analysis of Metabolic Disorders Therapeutics Market

4. Metabolic Disorders Therapeutics Market Macro Indicator Analysis

5. Global Metabolic Disorders Therapeutics Market by Disease Type

  • 5.1. Diabetes
  • 5.2. Obesity
  • 5.3. Hypercholesterolemia
  • 5.4. Lysosomal Storage Disease

6. Global Metabolic Disorders Therapeutics Market by Product

  • 6.1. Metachromatic Leukodystrophy
  • 6.2. Globoid Leukodystrophy
  • 6.3. Hepatic Encephalopathy
  • 6.4. Others

7. Global Metabolic Disorders Therapeutics Market by Region 2022-2028

  • 7.1. North America
    • 7.1.1. North America Metabolic Disorders Therapeutics Market by Disease Type
    • 7.1.2. North America Metabolic Disorders Therapeutics Market by Product
    • 7.1.3. North America Metabolic Disorders Therapeutics Market by Country
  • 7.2. Europe
    • 7.2.1. Europe Metabolic Disorders Therapeutics Market by Disease Type
    • 7.2.2. Europe Metabolic Disorders Therapeutics Market by Product
    • 7.2.3. Europe Metabolic Disorders Therapeutics Market by Country
  • 7.3. Asia-Pacific
    • 7.3.1. Asia-Pacific Metabolic Disorders Therapeutics Market by Disease Type
    • 7.3.2. Asia-Pacific Metabolic Disorders Therapeutics Market by Product
    • 7.3.3. Asia-Pacific Metabolic Disorders Therapeutics Market by Country
  • 7.4. RoW
    • 7.4.1. RoW Metabolic Disorders Therapeutics Market by Disease Type
    • 7.4.2. RoW Metabolic Disorders Therapeutics Market by Product
    • 7.4.3. RoW Metabolic Disorders Therapeutics Market by Sub-region

8. Company Profiles and Competitive Landscape

  • 8.1. Competitive Landscape in the Global Metabolic Disorders Therapeutics Market
  • 8.2. Companies Profiles
    • 8.2.1. Astazeneca Plc
    • 8.2.2. Novo Nordisk
    • 8.2.3. Sanofi
    • 8.2.4. Merck
    • 8.2.5. Eli Lily
    • 8.2.6. Abbvie
    • 8.2.7. Actelion Pharmaceuticals
    • 8.2.8. Amicus Therapeutics
    • 8.2.9. Arena Pharmaceuticals
    • 8.2.10. Biocon